2007
DOI: 10.1157/13102264
|View full text |Cite
|
Sign up to set email alerts
|

Pauta corta de isoniazida y rifampicina comparada con isoniazida para la infección latente de tuberculosis. Ensayo clínico aleatorizado

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
3
0

Year Published

2010
2010
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 29 publications
(4 citation statements)
references
References 16 publications
0
3
0
Order By: Relevance
“…A total of 35 publications describing 30 unique studies initially met eligibility criteria [5, 6, 20–52]. Totals of 16 studies ( n  = 44,149) [5, 20, 21, 23, 26, 29, 31, 32, 37, 4144, 46, 48, 49] and 14 studies ( n  = 44,128) [5, 20, 26, 27, 29, 3133, 37, 4144, 46] studies were included in the efficacy and completion NMAs, respectively. Thirteen studies met eligibility criteria but were judged to be heterogeneous related to aspects of endpoint definition, overlap of patients enrolled, treatment comparisons (which did not align with the network structure), and differences in patient population [6, 2325, 30, 34, 36, 39, 45, 47, 50–52]; a section of the review’s supplemental information (see Additional file 1) details these studies and their findings.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…A total of 35 publications describing 30 unique studies initially met eligibility criteria [5, 6, 20–52]. Totals of 16 studies ( n  = 44,149) [5, 20, 21, 23, 26, 29, 31, 32, 37, 4144, 46, 48, 49] and 14 studies ( n  = 44,128) [5, 20, 26, 27, 29, 3133, 37, 4144, 46] studies were included in the efficacy and completion NMAs, respectively. Thirteen studies met eligibility criteria but were judged to be heterogeneous related to aspects of endpoint definition, overlap of patients enrolled, treatment comparisons (which did not align with the network structure), and differences in patient population [6, 2325, 30, 34, 36, 39, 45, 47, 50–52]; a section of the review’s supplemental information (see Additional file 1) details these studies and their findings.…”
Section: Resultsmentioning
confidence: 99%
“…Amongst the 16 RCTs [5, 20, 21, 23, 26, 29, 31, 32, 37, 4144, 46, 48, 49] ( n  = 44,149) analyzed for efficacy, data from head-to-head trials were available for 21/36 (58.3%) of the possible pairwise comparisons in the network, with single studies informing several of the comparisons. Of the 14 RCTs ( n  = 44,128) used for the NMA of completion [5, 20, 26, 27, 29, 3133, 37, 4144, 46], head-to-head trials were available for 30/66 (45.5%) of the possible pairwise comparisons. The criteria used across studies to meet the endpoint of regimen completion ranged between 80 and 100% for the primary analysis.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Hence, drug-drug interactions should be monitored. Three months of daily INH plus rifampin has also been approved for LTBI therapy [ 26 ].…”
Section: Discussionmentioning
confidence: 99%